Keep in mind, GILD already has the planned GS-7977/TMC435 combo study with Tibotec/Medivir.
Right and I expect the results of those studies to be very good. Remember that VRUS initiated these studies and it's my opinion that GILD would prefer to develop in-house regardless of how exciting these results may be. If this is the case it would benefit ABT in providing them time to advance their combo.
Market Data 
Markets 
AI
